Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05458102 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05458102 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 18 participants.
The verdict
NCT05458102, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme \[CYP\]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on the study drug, vesatolimod (VES), in people with HIV-1 on antiretroviral therapy (ART).
Interventions
- DRUG Rifabutin
- DRUG Cobicistat
- DRUG Voriconazole
- DRUG Vesatolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-19 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05458102
The ClinicalTrials.gov registry entry for NCT05458102 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rifabutin is the first listed.
NCT05458102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05458102 about?
NCT05458102 is a clinical study titled "Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels". The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme \[CYP\]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on...
What is the current status of trial NCT05458102?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-08-19. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT05458102?
The interventions under investigation include: Rifabutin (DRUG), Cobicistat (DRUG), Voriconazole (DRUG), Vesatolimod (DRUG).
Who is sponsoring clinical trial NCT05458102?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.